Almanac 2012: Cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

Heart

Volumn 98, Issue 17, 2012, Pages 1272-1277

  Pell, Jill P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ARYLDIALKYLPHOSPHATASE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; FIBRINOGEN; LYSOPHOSPHOLIPASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PROADRENOMEDULLIN; SECRETORY PHOSPHOLIPASE A2; TROPONIN I;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FAMILY HISTORY; GENETIC MARKER; GENETIC RISK; HUMAN; INTERMETHOD COMPARISON; MEDICAL RESEARCH; PATIENT CODING; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CARDIAC SURGICAL PROCEDURES; CARDIOLOGY; CARDIOVASCULAR DISEASES; GENETIC MARKERS; HUMANS; PERIODICALS AS TOPIC; RISK ASSESSMENT; SOCIETIES, MEDICAL;

EID: 84864867814     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302143     Document Type: Review

References (43)

1. Parkes G. Using risk scores with patients. BMJ 2010;340:c3327.
2. Cooper A, Nherera L, Calvert N, et al . Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008.
3. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart 2011;97:442-4.
4. de la Iglesia B, Potter JF, Poulter NR, et al. Performance of the ASSIGN cardiovascular disease risk score on a UK cohort of patients from general practice. Heart 2011;97:491-9.
5. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010;340:c3442.
6. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefit or harms? A systematic review of the literature. BMC Health Serv Res 2008;8:60.
7. Liew SM, Doust J, Glasziou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart 2011;97:689-97.
8. Hippisley-Cox J, Coupland C, Robson R, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010; 341:c6624.
9. Bueno H, Fernandez-Aviles F. Use of risk scores in acute coronary syndromes. Heart 2012;98:162-8.
10. Fox KA, Eagle KA, Gore JM, et al; for the GRACE and GRACE2 Investigators. The Global Registry of acute coronary events, 1999 to 2009 e GRACE. Heart 2010;96:1095-101.
11. O'Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HFeACTION Predictive Risk Score Model. Circ Heart Fail 2012;5:63-71.
12. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospitality mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes 2010;3:25-32.
13. Van Dieren S, Beulens JW, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9.
14. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
15. Rana JS, Cole M, Despres JP, et al. Inflammatory biomarkers and the prediction of coronary event among people at intermediate risk: the EPICeNorfolk prospective population study. Heart 2009;95:1682-7.
16. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16. (Pubitemid 351679597)
17. Lorgis L, Zeller M, Dentan G, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. BMJ 2009;338:b1605.
18. Lorgis L, Cottin Y, Danchin N, et al. Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBMP) in patients with acute myocardial infarction. Heart 2011;97:551-6.
19. Tello-Montoliu A, Marin F, Roldan V, et al. The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage? Heart 2010;96:227-8.
20. Damman P, Beijk MA, Kuijt WJ, et al. Multiple biomarkers at admission significantly improves the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2011;57:29-36.
21. Brugts JJ, Akin S, Helming AM, et al. The predictive value of cardiac biomarkers in prognosis and risk stratification of patients with atrial fibrillation. Curr Opin Cardiol 2011;26:449-56.
22. Avellino A, Collins SP, Fermann GJ. Risk stratification and short-term prognosis in acute heart failure syndromes: a review of novel biomarkers. Biomarkers 2011;16:379-92.
23. Gustav Smith J, Newton-Cheh C, Almgren P, et al . Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010;56:1712-19.
24. Ketchum ES, Levy WC. Multivariate risk scores and patient outcomes in advanced heart failure. Congest Heart Fail 2011;17:205-12.
25. Haines DE, Wang Y, Curtis J. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications of death after implantable cardioverter-defibrillator implantation. Circulation 2011;123:2069-76.
26. Wilson SR, Lin FY, Min JK. Role of coronary artery calcium score and coronary CT angiography in the diagnosis and risk stratification of individuals with suspected coronary artery disease. Curr Cardiol Rep 2011;13:271-9.
27. Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011;97:1326-31.
28. Henriksson M, Palmer S, Chen R, et al. Assessing the cost-effectiveness of using prognostic biomarkers with decision markers: case study in prioritizing patients waiting for coronary artery surgery. BMJ 2010;340:b5606.
29. Ripatti S, Tikkanen E, Orho-Melander M, et al. A multi-locus genetic risk score for coronary heart disease: caseecontrol and prospective cohort analyses. Lancet 2010;376:1393-400.
30. Paynter NP, Chasman DI, Paré G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010;303:631-7.
31. Qi L, Ma J, Qi Q, et al. Genetic risk score and risk of myocardial infarction in Hispanics. Circulation 2011;123:374-80.
32. Thanassoulis G, Peloso GM, Pencina MJ, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calciumdthe Framingham Heart Study. Circ Cardiovasc Genet 2012;5:113-21.
33. Farooq V, Brugaletta S, Serruys PW. Utilizing risk scores in determining the optimal revascularization strategy for complex coronary artery disease. Curr Cardiol Rep 2011;13:415-23.
34. Farooq V, Brugaletta S, Serruys PW. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart 2011;97:1902-13.
35. Capodanno D, Tamburino C. Integrating the Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score into practice: use, pitfalls, and new directions. Am Heart J 2011; 161:462-70.
36. de Mulder M, Gitt A, van Domburg R, et al. EuroHeart score for the evaluation of inhospital mortality in patients undergoing percutaneous coronary intervention. Eur Heart J 2011;32:1398-408.
37. Garg S, Sarno G, Garcia-Garcia HM, et al. A new tool for the risk stratification of patients with complex coronary artery disease. The clinical SYNTAX score. Circ Cardiovasc Interv 2010;3:317-26.
38. Capodanno D, Caggegi A, Miano M, et al. Global risk classification and clinical SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) score in patients undergoing percutaneous or surgical left main revascularisation. J Am Coll Cardiol Intv 2011;4:287-97.
39. Chen SL, Chen JP, Mintz G, et al. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. J Am Coll Cardiol Intv 2010;3:632-41.
40. Chakravarty T, Buch MH, Naik H, et al. Predictive accuracy of SYNTAX score for predicting long-term outcomes of unprotected left main coronary artery revascularization. Am J Cardiol 2011;107:360-6.
41. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention. J Am Coll Cardiol 2010;55:1923-32.
42. Singh M, Holmes DR, Lennon RJ, et al. Development and validation of risk adjustment models for long-term mortality and myocardial infarction following percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:423-30.
43. Stolker JM, Kennedy KF, Lindsey JB, et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice. Derivation and validation of a risk model from the EVENT Registry. Circ Cardiovasc Interven 2010;3:327-34.